Re: More possible dilution
Well Jefferies last price target back in August was $4.
Jefferies analyst Biren Amin lowered the price target on Immunogen Inc. (NASDAQ: IMGN) to $4.00 (from $4.50) while maintaining a Hold rating.
Since they have selected a dose and schedule for imgn 632 and have plans to move into a phase 2b, then data must be good enough to continue on. Only question is could they get a fast track for BPDCN? Iím sure they will wait for that event to raise money. I suspect that and IMGN936 being a first in class have to move the stock price.